Inflectra

Infliximab, the active ingredient in Inflectra, is a TNF‑alpha inhibitor presented as an intravenous infusion for use in adult patients with autoimmune inflammatory disorders. It works by neutralising tumor necrosis factor‑alpha, reducing inflammation and disease activity in conditions such as rheumatoid arthritis and inflammatory bowel disease.

GNH USA supplies Inflectra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to maintain product integrity during global distribution.

Inflectra (infliximab) is a TNF‑alpha inhibitor used to treat several chronic inflammatory diseases. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve mucosal healing and symptom control. - Ankylosing spondylitis: alleviates spinal pain and improves mobility. - Psoriatic arthritis: diminishes joint swelling and skin lesions. - Plaque psoriasis: clears skin plaques and reduces scaling.

Inflectra may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Infusion‑related reactions: fever, chills, flushing. - Headache: mild to moderate intensity. - Nausea or vomiting. - Upper respiratory tract infection symptoms.

Serious or Rare Side Effects: - Severe infections, including tuberculosis reactivation. - Demyelinating disorders such as multiple sclerosis. - New or worsening heart failure. - Malignancies, particularly lymphomas. - Anaphylaxis or severe hypersensitivity reactions.

Before initiating Inflectra, several safety considerations should be observed. - Screen for active infections: evaluate for tuberculosis and hepatitis. - Monitor for signs of serious infection during therapy. - Assess cardiac function: avoid in patients with uncontrolled heart failure. - Evaluate malignancy risk: consider patient history of cancer. - Avoid live vaccines while receiving treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Inflectra can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Concurrent use of other TNF‑alpha inhibitors: increases immunosuppression. - Cytotoxic chemotherapy agents: heightens infection risk.

Moderate Interactions (Monitor Closely): - Methotrexate: may amplify liver toxicity. - Azathioprine or 6‑mercaptopurine: additive immunosuppressive effect. - Systemic corticosteroids: can further increase susceptibility to infections.